



## Triclabendazole Standard (DWT103)

This product is for research use only and is not intended for diagnostic use.

### PRODUCT INFORMATION

Conjugate	N/A
Cas.No	68786-66-3
Molecular Weight	359.7g/mol
Format	Liquid
Size	10 mg
Storage	Store unopened in freezer(-10 °C to 25 °C)

### BACKGROUND

Introduction	<p>Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans. Fascioliasis is a parasitic infection often caused by the helminth, <i>Fasciola hepatica</i>, which is also known as “the common liver fluke” or “the sheep liver fluke” or by <i>Fasciola gigantica</i>, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.</p>
Keywords	Triclabendazole; Anthelmintic drug; Fascioliasis